U.S. Viral Vector and Plasmid DNA Manufacturing Market Size Worth $ 11,315.21 Million by 2032 | CAGR: 19.9%

The U.S. viral vector and plasmid DNA manufacturing market size is expected to reach USD 11,315.21 million by 2032, according to a new study by Polaris Market Research. The report “U.S. Viral Vector and Plasmid DNA Manufacturing Market Size, Share, Trends, Industry Analysis Report, By Vector Type, By Disease (Cancer, Genetic Disorders, Infectious Diseases, Others), By Workflow, By Application, By End-Use, Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing prevalence of hereditary and infectious disorders has seen a substantial rise in the U.S. According to the National Institutes of Health, in 2019, approximately 100,000 individuals were diagnosed with sickle cell anemia in the U.S. The increasing utilization of gene therapy for treating viral infections like adeno-associated viruses, herpes simplex viruses, poxviruses, and retroviruses is expected to drive the adoption of gene therapies, thereby boosting the market growth for the production of viral vectors and plasmid DNA during the forecast period.

The global industry is experiencing a rise in the number of patients opting for gene therapy, leading to an increased demand for plasmid DNA for the research and development of gene therapy. Therefore, the production of plasmid DNA (pDNA) is crucial for lentivirus, Adeno-associated virus (AAV), and other viral vector systems. Furthermore, the prevalence of various infectious diseases on a worldwide scale has contributed to the expansion of the U.S. viral vectors and plasmid DNA manufacturing market share.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/us-viral-vector-and-plasmid-dna-manufacturing-market/request-for-sample

Furthermore, the U.S. market for viral vector and plasmid DNA manufacturing is undergoing substantial expansion due to the increasing need for vaccines and advanced therapeutic treatments. Government support and funding are instrumental in driving this growth. As a result, there has been a significant increase in the market share of U.S. viral vectors and plasmid DNA manufacturing.

Top of FormU.S. Viral Vector and Plasmid DNA Manufacturing Market Report Highlights

• In 2023, the cancer segment accounted for the largest revenue share in the U.S. viral vector and plasmid DNA manufacturing market as the rising prevalence of cancer has heightened the need for advanced treatments such as gene therapies and oncolytic viral therapies, which heavily utilize viral vectors and plasmid DNA.
• The pharmaceutical and biopharmaceutical companies category is expected to grow significantly over the forecast period. This is because gene therapies are expanding beyond rare genetic disorders to more common conditions, including cancers, cardiovascular diseases, and infectious diseases.
• The U.S. key market players include Bio-Rad Laboratories, Inc., Catalent Inc., Charles River Laboratories (Cobra Biologics), Genezen, Promega Corporation, RegenxBio, Inc., Revvity (SIRION Biotech), Thermo Fisher Scientific, Inc., Virovek Incorporation, and Waisman Biomanufacturing.

Polaris Market Research has segmented the U.S. viral vector and plasmid DNA manufacturing market report based on vector type, disease, workflow, application, and end-use.

U.S. Viral Vector and Plasmid DNA Manufacturing, Vector Type Outlook (Revenue - USD Million, 2019 - 2032)

• Adeno-Associated Virus (AAV)
• Adenovirus
• Lentivirus
• Others
• Plasmids
• Retrovirus

U.S. Viral Vector and Plasmid DNA Manufacturing, Disease Outlook (Revenue - USD Million, 2019 - 2032)

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others

U.S. Viral Vector and Plasmid DNA Manufacturing, Workflow Outlook (Revenue - USD Million, 2019 - 2032)

• Upstream Manufacturing

• Vector Amplification & Expansion
• Vector Recovery/Harvesting

• Downstream Manufacturing

• Fill Finish
• Purification

U.S. Viral Vector and Plasmid DNA Manufacturing, Application Outlook (Revenue - USD Million, 2019 - 2032)

• Antisense & RNAi Therapy
• Cell Therapy
• Gene Therapy
• Research Applications
• Vaccinology

U.S. Viral Vector and Plasmid DNA Manufacturing, End-Use Outlook (Revenue - USD Million, 2019 - 2032)

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

U.S. Viral Vector and Plasmid DNA Manufacturing Report Scope